Information sheet on the clinical study - INFINITY

Main indication

Advanced hematological diseases or solid tumors

Study name (study type)

INFINITY (registry platform)

Study sponsor

IOMEDICO

Registration number

ClinicalTrials.gov Identifier: NCT04389541

FOR BRIEF READERS:

Study for patients with advanced hematologic disease or solid tumors for whom no suitable standard therapy is available. Tissue samples of the patients’ tumors will be collected for future research projects. This is an observational study and has no influence on the treatment method prescribed by the physician

DETAILED INFORMATION

Study Title

Clinical Research Platform for Documenting Decision-Making in Biomarker-Based Precision Oncology and Its Clinical Significance

Which conditions are being studied?

Advanced hematological diseases or solid tumors

Are specific subgroups of patients with one of the aforementioned diseases being treated?

Patients with advanced hematologic disease or solid tumors for whom no suitable standard therapy is available

Background on the study medication

None

Study procedure.

Patients receive targeted therapy based on the molecular characteristics of the tumor. Additionally, patients provide tissue samples of their tumor for future research projects. The tissue samples will be collected in a so-called decentralized biobank and linked to the associated medical data

Inclusion criteria

• Patients with advanced hematologic disease or a solid tumor

- for whom no suitable standard therapy is available and 

- who have received targeted therapy (based on molecular diagnostics)

• Patients who are 18 years of age or older

Exclusion criteria

Patients who do not meet the inclusion criteria.

Your contacts: Investigators at the center and contact information

Prof. Dr. Dimitri Flieger

Email: flieger@~@gp-ruesselsheim.de

Phone: 06142 88-1456

Responsible staff members in the study clinic

Heike Borchert (Study Coordinator)

Email: borchert@~@gp-ruesselsheim.de

Phone: 06142 88-1032